Eye Eye 58 Million 360 Thousand Yuan To Buy Two Company Equity &Nbsp; Speed Up The Pace Of Expansion

In December 10th,

This is the second acquisition of Beijing's intelligence by AI eye department. Only a month ago, the eye ophthalmology acquired 91 million 944 thousand stake in Beijing's intelligence 71.4%, and officially entered Beijing to cut into the first tier cities in China.

After the acquisition is completed, the company will own 98.525% of Beijing's intelligence.

The company forecasts that the overall income of the Beijing intelligent project is better, with a payback period of 5.15 years (static) and a profit margin of 19.41%.

According to the announcement, Guiyang ophthalmology is mainly excimer laser for myopia. It has a certain status in the field of Ophthalmology. Its main business scope includes Western Ophthalmology, optometry and optometry, with a registered capital of 500 thousand yuan and a 100% stake in natural person Wang Mingzhan hospital.

The ophthalmology department intends to use the 23 million 450 thousand yuan of over raised funds, jointly with the former shareholder Wang Ming and new shareholder Lu lide to increase capital and expand the site. After the capital increase is completed, the company owns 70% of Guiyang ophthalmology.

Eyre ophthalmology believes that holding and expanding Guiyang ophthalmology will enable the company to enter the ophthalmic medical market in Guizhou province quickly, and echo with Kunming Eye Hospital, Chongqing eye eye hospital and Chengdu Er eye hospital to form the brand superiority and network superiority of the company in the southwest region.

It is estimated that the after tax investment recovery period (static) is 5.64 years and the investment profit margin is 15.95%.

China Merchants Securities Research Report said that the company acquired the wisdom of Beijing is very correct decision, Beijing market potential is huge, but the competition is also very fierce. The company choose to buy Beijing Ying Chi, a private hospital with certain influence in Beijing, will help the company quickly enter the Beijing market.

The acquisition of Beijing Ying Zhi will make the layout of the company more perfect in the whole country, and the linkage between the second and second tier cities will form a synergy effect.

The eye ophthalmology has obtained abundant funds through IPO, which raised 938 million yuan in total, and raised 542 million yuan in excess of funds. This made the company change from the mode of building new hospital with its own capital to the way of "new + acquisition", and the pace of expansion was obviously accelerated. The acquisition has become an important means of public Si Kuozhang.

According to the company announcement, after the completion of the acquisition, the company's remaining funds raised 172 million 770 thousand yuan.